Compass Therapeutics, Inc. Segments Disclosure
|
15. |
Segment Information |
Segment reporting is prepared on the same basis that our chief executive officer, who is our CODM, manages the business, makes operating decisions and assesses performance. The Company operates in segment. The Company’s business is research and development of drug candidates. Costs, including supplies, outsourced development, and other research and development costs are tracked by major program. While internal personnel costs are tracked by program for overall program spending, it is not broken out for management review. Facility and equipment costs are not allocated to programs. Research and development expenses are summarized by program in the table below:
|
Year Ended December 31, |
||||||||
|
2025 |
2024 |
|||||||
|
(000's) |
||||||||
|
Licensing revenue |
$ | — | $ | 850 | ||||
|
Personnel |
11,935 | 9,918 | ||||||
|
General |
4,616 | 3,965 | ||||||
|
Tovecimig |
23,680 | 23,177 | ||||||
|
CTX-471 |
4,183 | 2,879 | ||||||
|
CTX-8371 |
3,355 | 2,403 | ||||||
|
CTX-10726 |
8,200 | — | ||||||
|
Research and development |
55,969 | 42,342 | ||||||
|
Personnel |
10,236 | 10,472 | ||||||
|
General |
6,634 | 4,661 | ||||||
|
General and administrative |
16,870 | 15,133 | ||||||
|
Other income |
6,350 | 7,250 | ||||||
|
Net loss |
$ | (66,489 | ) | $ | (49,375 | ) | ||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 5, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.